

Sustained seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood donors

M Carmen Martín ¹

M Isabel González ¹

Nuria Holgado ¹

Ana I Jimenez ¹

Nuria Ortega ¹

Isabel Page ¹

Alba Parrado¹

María Pérez ¹

Lydia Blanco-Peris ¹

¹Centro de Hemoterapia y Hemodonación de Castilla y León

Running Title: Seroprevalence of anti SARS-CoV-2 in asymptomatic blood donors

Keywords: total immunoglobulins, SARS-CoV-2, seroprevalence, blood donors

Corresponding author: M Carmen Martín; cmartinalo@saludcastillayleon.es; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos, Valladolid, Spain

Sustained seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood donors

1 Abstract

2 **Background:** Seroprevalence analysis of SARS-CoV-2 is one of the keys to
3 accurately monitor pandemics and help the authorities make health decisions and
4 adjust the current social interventions. The aim of this study was to determine
5 retrospective seroprevalence evolution among blood donors along prepandemic
6 months, and the first wave in Spain. A secondary objective was to determine
7 whether age, blood group or haematological parameters are related to recent
8 past infection.

9 **Material and Methods:** A total of 12719 donations SARS-CoV-2 from July 2019
10 to October 2020 were analysed. Donors were 60.9% males and their average
11 age was 46+/-13. An automated chemiluminescence double-antigen sandwich
12 immunoassay for the in vitro semi quantitative detection of total antibodies to
13 SARS-CoV-2 in human serum and plasma was performed.

14 **Results:** Seropositivity donation rate grew up from week 11 to week 21, reaching
15 plateau by near 8% donations, sustained until week 43 when 2nd wave arose in
16 our country. 6.7% individuals were positive by the end of 1st wave. No
17 differences by sex age or blood group were found regarding antibodies.
18 Lymphocyte were significantly higher in positive woman as compared to negative
19 ones and haemoglobin were lower in positive men as compared to negative
20 ones.

21 **Discussion:** Seroprevalence due to asymptomatic cases would be equivalent to
22 that of general population. Sex and age would not affect COVID-19 susceptibility
23 but its severity. Gender differences are present even in asymptomatic individuals:
24 females are possibly protected by their relative lymphocytosis and neutropenia
25 whereas males are would be weaker as seropositive men show a decrease of
26 haematocrit and haemoglobin. Further studies are needed to confirm these
27 gender differences not only in severe but as well in asymptomatic cases as they
28 can help better understand COVID19 pathogenesis and prognosis.

29

30 Introduction

31 SARS-CoV-2 infection curses asymptomatic or with just mild symptoms in a
32 number of cases. This make it hard to calculate accurate infection or fatality rates
33 and prevalence. These calculations are important for evaluating risks of COVID-
34 19 disease, predicting the spread of the virus and managing health resources ¹.

35 Most cases develop an effective immune response during infection, leading to
36 viral eradication and the production of specific T cell responses and antibodies
37 against SARS-CoV-2 that are usually detectable 10–21 days after infection.

38 Antibody assays are quite different: they either detect antibodies against different
39 viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG,
40 IgM, IgA or their combinations. To make it even messier, many factors can
41 influence test performance, including cross-reactivity with other coronaviruses or
42 platform (laboratory-based vs point-of-care, lateral flow). Chemiluminescence
43 assays have suitable performances regarding both sensibility and sensitivity,

44 even though those values have been estimated as testing populations with
45 compatible symptoms and would be presumably lower when performing
46 serosurveillance analysis on apparently healthy population. Chemiluminiscent
47 immunoassays exhibit a significantly higher specificity score but a lower
48 sensitivity, as compared to ELISA immunoassays. Moreover, immunoassays
49 detecting IgG antibodies against SARS-CoV-2 N protein instead of S protein
50 alone are more reliable, considering both specificity and sensitivity scores ².

51 SARS-CoV-2 disease burden is suspected to be much larger than reported
52 COVID-19 cases due to low detection rates, especially at the beginning of
53 pandemics. Seroprevalence surveys are needed to monitor the pandemic, both
54 before and after vaccination strategies. ³ Reported COVID-19 cases do not
55 represent the full SARS-CoV-2 disease burden. Case reports are dependent on
56 patients seeking health care, massive local screenings or regional tracking
57 activities. Analysis of data from seroprevalence and serosurveillance is a
58 common strategy for estimating underreporting and real disease burden. There
59 are several features that should be taken into account, including time between
60 infection and antibody development or antibody waning, which must be
61 considered to understand seroprevalence surveys avoiding biases as. Any
62 seroprevalence survey should be evaluated for selection bias. Serological
63 surveys with a random sampling design of the general population are difficult to
64 perform in a pandemic, but a random sampling design of the general population
65 yields a seroprevalence estimate least likely to be affected by selection bias.
66 Blood donors are a quite representative subset of general population aged 18-65.

67 Blood donor-based serosurveillance is a powerful and cost-effective strategy to
68 monitor infectious diseases. There are quite a lot of infections for which routine
69 donor screening is well known to be useful, including human immunodeficiency
70 virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-
71 lymphotropic virus (HTLV), and West Nile virus (WNV) ¹, babesiosis or Crimean-
72 Congo fever. The use of blood donor samples means we're sampling mainly
73 asymptomatic and recovered cases of COVID-19 (normal blood donation is
74 allowed after 28 days following COVID-19 symptoms' resolution).

75 Heterogeneity of susceptibility and transmission is hard to evaluate but does
76 exist⁴. A portion of the population is not susceptible to infection from the first
77 pathogen contact. Some may have pre-existing immunity via cross-reactivity or
78 particular host factors such as mucosal immunity or trained innate immunity
79 protection (as it has been reported to be conferred by DTP or BCG vaccination ⁵).
80 There is as well a proportion of seronegative individuals that will develop
81 immunity by T cell mediated responses but without exhibiting an antibody
82 response ⁶.

83 Castilla y Leon, with a population of 2.299.598 inhabitants, has accumulated
84 221.816 confirmed cases (<https:// analisis.datosabiertos.jcyl.es/>), with an overall
85 case-fatality rate of 4.85 to date.

86 Our institution, Centro de Hemoterapia de Castilla y León keeps within its
87 Biobank serum samples from every single donor along the last ten years, that
88 makes up around 1 million sera together with their demographical data such as
89 sex or age and laboratory parameters (blood counts, blood group, haemoglobin,
90 etc...) . The Biobank of the Centro de Hemoterapia de Castilla y León is included
91 in the National Registry of Biobanks (RD17 / 16/2011) with the number

92 B.0000264 and holds an ISO 9001: 2015 certification endorsing our granting of
93 safety and traceability of any human biological sample we distribute, always
94 behaving Spanish and European rules on human samples and data protection
95 management.

96 The starting hypothesis is the existence of a certain number of asymptomatic
97 carriers of the SARS-CoV-2 virus that would develop antibodies against the new
98 coronavirus ⁶ (and subsequently contribute to herd immunity). There are recently
99 described early cases in France ⁷, arising the question of whether the pathogen
100 could have been circulating even before the official recording of the first cases in
101 Spain by January 31st, 2020.

102 The main aim of this study is to detect serum antibodies to determine what
103 percentage of the population has had contact with the virus at different times and
104 has therefore developed antibodies against it. A secondary goal is to establish
105 whether sex, age, blood group or haematological abnormalities are related to
106 recent past infection. This epidemiological features would make it possible to
107 optimize hospital management of COVID19 cases, make a good forecast of
108 resources for possible future outbreaks, and would facilitate decisions in the
109 social sphere by reliably knowing the percentage of immunized patients.

110 **MATERIALS AND METHODS**

111 *Aim, design and setting of the study*

112 The aim of this study was to obtain, a reliable knowledge of asymptomatic
113 COVID-19 cases and their immunological and haematological characteristics,
114 seroprevalence, rate of positive donations and its temporal evolution along the
115 first wave. So, a retrospective observational analysis was performed.

116 *Participants*

117 The study population comprised randomised samples from blood, plasma
118 (excluding convalescent) and platelet donations from July 2019 to October 2020.
119 A total of 12718 samples of 11444 donors over 18 years old were included.

120 *Data collection*

121
122 All haematological and demographical data were extracted from electronic
123 medical records. The collection form included age, sex, blood group, and
124 laboratory data.

126 *Laboratory data an analyses*

127
128 Major laboratory markers were extracted from medical records. Routine blood
129 examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet,
130 monocyte, eosinophil and basophil counts (cells*10³/μL) and their percentages.
131 Serum biochemical tests recorded were immunoglobulins IgG, IgA and IgM
132 (mg/dL). Haemoglobin (Hb), haematocrit (HCT) and corpuscular mean volume
133 were analysed as well. An automated chemiluminescence double-antigen
134 sandwich immunoassay for the in vitro semi quantitative detection of total
135 antibodies to SARS-CoV-2 in human serum and plasma was performed. Target
136 antigen of the immunoassay is a recombinant nucleocapsid (N) protein. Elecsys®
137 Anti-SARS-CoV-2 detects antibodies correlating with virus-neutralizing ones and
138 is therefore useful to help characterize the immune reaction to SARS-CoV-2 ^{9,10}.
139 Immunoassay was validated by testing of 6 pairs of samples (plasma EDTA and

140 serum) from diagnosed PCR-positive, symptomatic cases infected by mid-April,
141 that were previously reported positive by the CMV, and checked to be as well
142 positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S) and IgA (ELISA,
143 S protein, Euroimmun) antiSARS-CoV-2 and another set of ten prepandemic
144 samples therefore supposed to be negative. A 100% concordance was yielded by
145 these validation assays. The cut-off was that recommended by manufacturer
146 (OD>1 to report reactivity).

147

148 *Statistical analysis*

149

150 Demographic and clinical characteristics of patients were expressed as their
151 mean/median and standard deviation (SD) for continuous variables and
152 frequency distributions are reported for categorical variables. Age was analysed
153 both as continuous and categorical variable; in the latter case was recoded into 4
154 groups: <30, 30-45, 45-60, 60-75 years old.

155 Kolmogorov-Smirnov test was performed on each continuous variable to contrast
156 normality and only IgG and IgM followed normal distributions, therefore non-
157 parametric Krusal-Wallis test was performed to compare laboratory values. To
158 contrast the Ho of independence within categorical variables, Pearson's Chi-
159 square and Fisher's exact test were carried out.

160

161 *Ethics approval*

162

163 This study was conducted according with national regulations, institutional
164 policies and in the tenets of the Helsinki Declaration. This study was approved,
165 with the Valladolid Health Area Drug Research Ethics Committee acting as the
166 main committee, in a meeting held on June 11, 2020 with the reference number
167 "BIO-2020-93".

168

169 *Availability of data and materials*

170

171 Data collected for the study, including fully anonymized participant data, are
172 available to others. Data available include fully anonymized participant data and
173 data dictionary. Related documents are available from the date of publications
174 henceforth: study protocol, statistical analysis, and approval of Ethical Board.
175 These documents are available from the date of publications henceforth at email
176 address cmartinalo@saludcastillayleon.es. Data would be shared after approval
177 of proposals by the Valladolid Este Ethical Committee.

178

179 *Abbreviations.*

180 Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM);
181 polymerase chain reaction (PCR); standard deviation (SD); interquartile range
182 (IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean
183 corpuscular volume (MCV).

184

185

186

187 **Results**

188 A total of 12718 donations (either whole blood, plasmapheresis or platelet
189 apheresis) were tested for total anti SARS-CoV2 antibodies. Donors made up
190 11444, 60.91% males, aged 18-75, average 46+/-13, 45.8%A, 40.3% O,

191 10.56%B, 3.31%AB. 660 out of 9886 single donors were positive within weeks 11
192 to 43, that makes a seroprevalence of 6.73% at the end of the first wave.

193 Donations collected since 19/07/2019 (week -24) to 19/10/2020 (week 43) were
194 analysed

195 Seropositivity rate grew up from week 11 to week 21, reaching a 7.8% plateau,
196 with just subtle changes until week 43 when 2nd wave arose in our country.
197 Plateau was reached by the last week of May 2020, 11 weeks after close
198 lockdown in Spain, that begun in March, 15th and 17 weeks after 31/01, the date
199 of the first declared case. As can be seen in Figure 1, a pronounced slope can be
200 appreciated from then to plateau at week 22.

201 Three donations yielded positive results along 2019 (July, September and
202 October) but none of them were positive when testing separately IgG, IgA or IgM.
203 Their OD were 1.05, 1.08 and 5.46 respectively. 1142 donations from year 2019
204 were analysed.

205 No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of
206 donors were found (Table I)

207 Immunoglobulin levels didn't show any differences as comparing positive and
208 negative donations but haemoglobin (14.9 vs 17.7 g/dL; $p<0.05$) and haematocrit
209 (45.2% vs 44.4%) were both significantly lower in positive donations
210 (Supplementary Table I). WBC were slightly lower (7.5 vs 7.2 cells* $10^3/\mu\text{L}$;
211 $p<0.02$).

212 As splitting data by sex, the fact arose that lower haemoglobin (46.8% vs 45.9%;
213 $p<0.05$) and haematocrit (15.5 vs 15.3 g/dL; $p<0.05$) were significantly different
214 just in males and that positive females had significantly lower WBC (7.67 vs 7.25
215 cells* $10^3/\mu\text{L}$) and neutrophil numbers (4.53 vs 4.27 cells* $10^3/\mu\text{L}$) and percent,
216 and conversely, a higher lymphocyte percent as a trend (31.7% vs 33.10%;
217 $p<0.2$) with significantly lower count (2.39 vs 2.35 cells* $10^3/\mu\text{L}$ $p<0.05$). A trend
218 of lower platelet count in positive women was observed (261 vs 255
219 cells* $10^3/\mu\text{L}$; $p<0.02$) and monocyte (0.46 vs 0.44 cells* $10^3/\mu\text{L}$) and higher
220 monocyte (0.4 vs 0.5 cells* $10^3/\mu\text{L}$). No other significant differences were found
221 either in males, females or overall.

222 Discussion

223 A seroprevalence around 6.73% (7.8% of donations) was reached and sustained
224 in our region regarding 18-75 years old population without COVID-19
225 antecedents. This fact agrees with the seroprevalence study ENE-COVID19
226 promoted by the *Instituto Nacional the Epidemiología*¹¹, where is reported that a
227 7.2% of the participants in our region would have anti SARS-CoV2 IgG antibodies
228 by the end of June. It is to notice that almost $\frac{1}{4}$ people in our region (25.51%
229 according to National Institute of Statistics, INE 2020 data) is older than 65 and
230 are necessarily underrepresented in this study as it comprises blood donors. That
231 happens as well with population under 18 (under 4.5%).

232 The first case in Spain was reported on 31/01/2020, but 3 positive donations
233 were found as testing samples collected along 2019. That could be meaningful in
234 two opposite ways: one possible explanation would be cross reactivity to
235 seasonal cold coronaviruses and the other would be that SARS-COV-2 would
236 have been circulating at least since 2019 summer.

237 Although the possibility of cross reactivity has been widely commented in mass
238 media, little scientific literature can be found to date. It has been checked that
239 long-term cross-reactive both T-cell and antibodies can be a correlate of
240 protections against COVID-19⁸. It will be therefore important to determine the
241 magnitude and prevalence of this correlates to accurately determine the
242 immunization status of populations, the so named herd immunity.

243 There are as well reports about SARS-CoV-2 circulating in Europe along 2019.
244 Italy's Ministry of Health reported high levels of "unusual" strains of flu and
245 pneumonia concentrated in the area around Milan and appearing in 17 of Italy's
246 20 regions¹². Our three donors would be even earlier cases.

247 Conversely to clinical forms of COVID-19¹³ neither age nor sex have an
248 influence on the probability to develop an asymptomatic infection. Another
249 seroprevalence reports from european countries support this feature¹⁴⁻¹⁸. It may
250 be therefore ascertained that age and sex do not have a role in SARSCoV-2
251 infection susceptibility, but only in their progression to severe forms.

252 Blood group has been reported elsewhere^{6, 19, 20} to confere susceptibility or
253 determine severity (most studies do not split these two concepts) to SARS-CoV2
254 infection. Relationship with susceptibility is not supported by our data. We
255 excluded convalescent plasma donors, opposite to other studies, that focused
256 into these donors²⁰. Perhaps blood group might be related only to clinical cases
257 and therefore linked to severity but not related to asymptomatic infection. Another
258 surface antigens such as HLA or KIR might be as well involved and should be
259 studied.

260 Several blood count anomalies have been reported to be associated to SARS-
261 CoV2 infection, notably lymphopenia and neutrophilia²¹. Conversely, our data
262 reveal that asymptomatic positive women had a significant neutropenia and
263 lymphocytosis as compared to negative ones. Perhaps this feature is a correlate
264 of protection against clinical severity. Mortality in COVID-19 is associated to low
265 haemoglobin²². In our series, haemoglobin and haematocrit were present just in
266 positive males as compared to negative ones. A hampering in O2 transport due
267 to hem- group²³ destruction has been reported to be responsible for that bad
268 prognosis. It seems as if males were more labile to this damage after infection,
269 being this effect visible even when no symptoms are present.

270 **Conclusions**

271 We can conclude that seroprevalence due to asymptomatic cases is equivalent to
272 that of general population. Sex and age would not affect COVID-19 susceptibility
273 but its severity. Gender differences are present even in asymptomatic individuals:
274 females are possibly protected by relative lymphocytosis and neutropenia
275 whereas males are would be weaker as seropositive men show a decrease of
276 haematocrit and haemoglobin. Further studies are needed to confirm these
277 gender differences not only in severe but as well in asymptomatic cases as they
278 can help better understand COVID19 pathogenesis and prognosis.

279

280 **Acknowledgements**

281 The authors thank to all blood donors making this work possible by allowing
282 research use of their samples by the Biobanco del Centro de Hemoterapia y

283 Hemodonación de Castilla y León. They also thank the staff in charge of blood
284 donation, and lab technicians for their efforts and Roche for its support.

285 **Funding and resources**

286 This work has been carried out provided free equipment and test reagents from
287 Roche Diagnostics International Ltd.

288 **Authors' contributions**

289 LB and MCM conceived the idea for this study, designed the protocol, analysed
290 the data and drafted the manuscript. IP, AJ and MIGF were in charge of
291 laboratory data. All authors provided critical revisions and approved the final
292 version of the manuscript.

293 **Disclosure of conflicts of interest**

294 Authors stated no conflicts of interest although M Carmen Martin will speak about
295 this issue in a sponsored symposium of Roche Diagnostics International Ltd.

296

297

298

299 **References**

300

- 301 1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory
302 Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood
303 Donor Populations. *Clin Infect Dis*. 2020;**72(2)**:254-256
- 304 2. Speletas M, Kyritsi MA, Vontas A, et al. Evaluation of Two
305 Chemiluminescent and Three ELISA Immunoassays for the Detection of
306 SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and
307 Patients' Management. *Front Immunol*. 2020;**11**:609242
- 308 3. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections,
309 Symptomatic Infections, Hospitalizations, and Deaths Using
310 Seroprevalence Surveys. *JAMA Netw Open*. 2021;**4(1)**:e2033706
- 311 4. Friston K, Costello A, Pillay D. 'Dark matter', second waves and
312 epidemiological modelling. *BMJ Glob Health*. 2020;**5(12)**:e003978
- 313 5. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care
314 providers and the protection against COVID-19. *J Clin Invest*.
315 2021;**131(2)**:e145545
- 316 6. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilis J, Candon S,
317 Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with
318 Cellular Immune Response without Seroconversion, France. *Emerg Infect*
319 *Dis*. 2021;**27(1)**:113–21

- 320 7. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X.
321 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O
322 French blood donors. *Antiviral Res.* 2020;181:104880
- 323 8. Poonia B, Kottlilil S. Immune Correlates of COVID-19 Control. *Front*
324 *Immunol.* 2020;11:569611
- 325 9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical
326 evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin*
327 *Virol.* 2020;129:104480
- 328 10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2
329 serological assays in a high-prevalence setting [published online ahead of
330 print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis.* 2021;1-9
- 331 11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk
332 for SARS-CoV-2 in community dwelling population of Spain: nationwide
333 seroepidemiological study. *BMJ.* 2020;371:m4509.
334
- 335 12. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in
336 emergency departments as a COVID-19 surveillance system: a time series
337 study. *BMJ Open.* 2021;11(2):e044388.
- 338 13. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-
339 reactive protein, and lymphocytes as key clues from a multicentre retrospective
340 study. *Immun Ageing.* 2020;17:22
341
- 342 14. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID-
343 19 in Scotland: population-based seroprevalence surveillance for SARS-
344 CoV-2 during the first wave of the epidemic. *Public Health.* 2021;190:132-
345 134
- 346 15. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in
347 Brazil: results from two successive nationwide serological household
348 surveys. *Lancet Glob Health.* 2020;8(11):e1390-e1398.
- 349 16. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey
350 of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro*
351 *Surveill.* 2020;25(31):2001369
- 352 17. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community
353 Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April
354 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(29):965-970
- 355 18. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-
356 CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a
357 population-based study. *Lancet.* 2020;396(10247):313-319
- 358 19. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood
359 Types and COVID-19: Spurious, Anecdotal, or Truly Important
360 Relationships? A Reasoned Review of Available Data. *Viruses.*
361 2021;13(2):160

- 362 20. Muñiz-Diaz E, Llopis J, Parra R, et al. Relationship between the ABO blood
363 group and COVID-19 susceptibility, severity and mortality in two cohorts
364 of patients. *Blood Transfus.* 2021;**19**(1):54-63
- 365
- 366 21. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From
367 cytopenia to coagulopathy. *Eur J Haematol.* 2020;**105**(5):540-546
- 368 22. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving
369 Reactive Oxygen Species and Myeloperoxidase Explains Clinical
370 Deterioration and Fatality in COVID-19. *Int J Biol Sci.* 2021 Jan 1;**17**(1):62-
371 72
- 372 23. Dattilo M. The role of host defences in Covid 19 and treatments
373 thereof. *Mol Med.* 2020;**26**(1):90
- 374
- 375
- 376

377 **Tables**

378

	Negative		Positive	
	n	%	n	%
Female	4531	38,1%	164	40,3%
Male	7375	61,9%	243	59,7%
<30	3551	29,8%	104	25,6%
30 to 45	5036	42,3%	180	44,2%
45 to 60	1151	9,7%	42	10,3%
60 to 75	2168	18,2%	81	19,9%
A	5411	45,5%	198	48,6%
AB	423	3,6%	16	3,9%
B	919	7,7%	22	5,4%
O	5151	43,3%	171	42,0%

379 Table I. Sex, age range and blood group of positive/negative anti SARS-COV2 donations
380 analysed

381

382

383

384

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	45.8	12.8	34.2-54.2
	Positive	407	44.2	46.5	13.0	32.8-54.8
IgA	Negative	194	236.9	223.5	101.3	163-292
	Positive	5	224.4	274.0	92.3	134-282
IgG	Negative	194	1065.4	1037.5	217.4	910-1185
	Positive	5	1123.8	1095.0	249.9	924-1229
IgM	Negative	194	113.3	100.5	64.8	69-138
	Positive	5	103.0	89.0	41.7	78-97
WBC	Negative	11219	7.5	7.2	1.8	6.16-8.5
	Positive	386	7.2	7.1	1.6	6.15-8.22
Hb*	Negative	11218	14.9	14.9	1.3	14-15.8
	Positive	386	14.7	14.7	1.2	13.8-15.4
Hematocrite*	Negative	11218	45.1	45.2	3.5	42.7-47.6
	Positive	386	44.5	44.4	3.5	42.3-46.6
Platelets	Negative	11217	247.9	243.0	54.3	211-280
	Positive	386	247.3	242.5	55.7	206-276
Neutrophil count (t)	Negative	11217	4.4	4.3	1.4	3.44-5.19
	Positive	386	4.3	4.2	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	58.9	7.5	53.8-63.9

Lymphocyte count	Positive	386	58.5	58.7	7.1	54.3-63.4
	Negative	11216	2.3	2.3	0.7	1.86-2.72
Lymphocyte %	Positive	386	2.3	2.2	0.6	1.89-2.64
	Negative	11216	31.7	31.5	6.9	27-36.2
Monocyte count	Positive	386	32.1	32.4	6.6	27.3-36.1
	Negative	11216	0.5	0.46	0.1	0.38-0.56
Monocyte %	Positive	386	0.5	0.46	0.1	0.37-0.54
	Negative	11216	6.5	6.4	1.5	5.5-7.4
Eosinophil count	Positive	386	6.5	6.4	1.4	5.5-7.3
	Negative	11217	0.2	0.2	0.1	0.09-0.23
Eosinophil %	Positive	386	0.2	0.1	0.1	0.09-0.22
	Negative	11217	2.5	2.1	1.8	1.3-3.2
Basophil count	Positive	386	2.4	2.0	1.7	1.3-3.1
	Negative	11217	0.0	0.0	0.0	0.02-0.04
Basophil %	Positive	386	0.0	0.0	0.0	0.02-0.04
	Negative	11217	0.5	0.5	0.2	0.3-0.6
	Positive	386	0.5	0.5	0.3	0.4-0.6

385 *p<0.001

386 (t)p<0.2

387 Supplementary Table I. Descriptive analysis of age, immunoglobulins (mg/dL),

388 Hb(g/dL), MCV, hemogram counts (cells*10³/μL) and percents, of reactive and non-

389 reactive donations

390

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	43.50	13.3	30.3-53.3
		Positive	164	42.1	45.39	13.6	28.6-53.1
	Male	Negative	7375	45.2	46.81	12.2	36.7-54.8
		Positive	243	45.7	46.98	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	200.00	97.0	157-250
		Positive	3	235.3	274.00	105.5	116-316
	Male	Negative	140	245.6	233.50	101.9	176.5-302.5
		Positive	2	208.0	208.00	104.7	134-282
IgG	Female	Negative	54	1076.4	1062.50	191.3	964-1186
		Positive	3	1082.7	1095.00	152.9	924-1229
	Male	Negative	140	1061.2	1029.00	227.2	903-1181.5
		Positive	2	1185.5	1185.50	436.3	877-1494
IgM	Female	Negative	54	143.1	129.50	64.6	94-169
		Positive	3	114.3	89.00	53.7	78-176
	Male	Negative	140	101.8	90.00	61.3	64.5-121
		Positive	2	86.0	86.00	15.6	75-97
MCV	Female	Negative	3618	91.2	91.50	4.8	88.4-94.4
		Positive	142	91.2	91.40	4.1	88.9-93.5
	Male	Negative	6141	90.9	91.00	4.6	88.1-93.8

		Positive	204	90.6	91.00	4.8	88-94.1
WBC	Female*	Negative	4270	7.8	7.67	1.9	6.48-8.96
		Positive	157	7.5	7.25	1.5	6.28-8.57
	Male	Negative	6949	7.2	7.02	1.8	5.99-8.2
		Positive	229	7.1	6.98	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	13.80	0.9	13.2-14.4
		Positive	157	13.7	13.80	0.9	13.2-14.3
	Male*	Negative	6949	15.5	15.50	1.0	14.9-16.2
		Positive	229	15.3	15.30	1.0	14.7-15.8
HCT	Female	Negative	4269	42.4	42.30	2.7	40.6-44
		Positive	157	42.1	42.00	2.5	40.5-43.6
	Male*	Negative	6949	46.8	46.80	2.8	45-48.6
		Positive	229	46.2	45.90	3.0	44.3-47.7
PLT	Female	Negative	4268	265.9	261.00	56.6	228-300
		(t) Positive	157	261.0	255.00	60.5	219-296
	Male	Negative	6949	236.8	233.00	49.6	204-266
		Positive	229	237.9	234.00	50.2	203-266
Neutrophil count	Female*	Negative	4268	4.7	4.53	1.4	3.65-5.47
		Positive	157	4.4	4.27	1.2	3.56-5.08
	Male	Negative	6949	4.3	4.10	1.4	3.34-4.95
		Positive	229	4.2	4.10	1.2	3.24-4.97
Neutrophil %	Female	Negative	4268	59.2	59.40	7.4	54.2-64.3
		Positive	157	58.1	58.10	7.2	54-62.9
	Male	Negative	6949	58.6	58.70	7.5	53.6-63.6
		Positive	229	58.8	58.70	7.0	54.6-63.5
Lymphocyte count	Female*	Negative	4267	2.5	2.39	0.7	1.97-2.88
		Positive	157	2.4	2.35	0.6	2.02-2.81
	Male	Negative	6949	2.2	2.18	0.6	1.8-2.62
		Positive	229	2.2	2.17	0.6	1.8-2.51
Lymphocyte %	Female	Negative	4267	32.0	31.70	6.9	27.4-36.5
		(t) Positive	157	33.0	33.10	7.0	28.4-37
	Male	Negative	6949	31.5	31.30	6.9	26.8-36.1
		Positive	229	31.4	31.70	6.3	26.7-35.6
Monocyte count	Female	Negative	4267	0.5	0.46	0.1	0.37-0.55
		(t) Positive	157	0.5	0.44	0.1	0.36-0.52
	Male	Negative	6949	0.5	0.46	0.1	0.38-0.56
		Positive	229	0.5	0.47	0.1	0.38-0.55
Monocyte %	Female	Negative	4267	6.1	6.00	1.4	5.1-6.9
		Positive	157	6.1	6.00	1.4	5.2-6.9
	Male	Negative	6949	6.7	6.60	1.5	5.7-7.6
		Positive	229	6.7	6.70	1.4	5.8-7.6
Eosinophil	Female	Negative	4268	0.2	0.14	0.1	0.09-0.21

count		Positive	157	0.2	0.13	0.1	0.09-0.19
	Male	Negative	6949	0.2	0.16	0.1	0.1-0.24
		Positive	229	0.2	0.15	0.1	0.09-0.23
Eosinophil %	Female	Negative	4268	2.2	1.80	1.6	1.2-2.8
		Positive	157	2.3	1.80	1.7	1.1-2.8
	Male	Negative	6949	2.7	2.20	1.8	1.4-3.4
		Positive	229	2.5	2.10	1.7	1.4-3.2
Basophil count	Female	Negative	4268	0.0	0.03	0.0	0.02-0.05
		Positive	157	0.0	0.04	0.0	0.02-0.05
	Male	Negative	6949	0.0	0.03	0.0	0.02-0.04
		Positive	229	0.0	0.03	0.0	0.02-0.04
Basophil %	Female	Negative	4268	0.5	0.40	0.2	0.3-0.6
	(t)	Positive	157	0.5	0.50	0.3	0.3-0.6
	Male	Negative	6949	0.5	0.50	0.2	0.3-0.6
		Positive	229	0.5	0.50	0.2	0.4-0.6

391 *p<0.001

392 (t)p<0.2

393 Supplementary Table II. Descriptive analysis of age, immunoglobulins (mg/dL),
 394 Hb(g/dL), MCV, hemogram counts (cells*10³/μL) and percents, of reactive and non-
 395 reactive donations by sex

396 Figures

397 Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal
 398 series' model (mobile median t=6; exponential smoothing model R²=0.991;p<0.001)

399

